Table.
Comparison of patients with 6-month prepubertal versus pubertal US LH at baseline and 12 months
| All patients at baseline (n = 33) | Prepubertal LH at baseline (n = 12) | Pubertal LH at baseline (n = 17) | All patients at 12 months (n = 32) | Prepubertal LH at 12 months (n = 12) | Pubertal LH at 12 months (n = 17) | |
|---|---|---|---|---|---|---|
| Sex, n (%) | M: 7 (21) F: 26 (79) |
M: 2 (17) F: 10 (83) |
M: 5 (29) F: 12 (71) |
|||
| Age at implantation, years, mean ± SD | 7.2 ± 2.5 | 7.4 ± 2.6 | 7.0 ± 2.4 | |||
| Previous GnRHa therapy, n (%) | 12 (39) | 5 (42) | 5 (29) | |||
| CNS abnormality on imaging, n (%) | 4 (13) | 3 (25) | 1 (6) | |||
| BMI, kg/m2, mean ± SD | 18.3 ± 3.8 | 19.6 ± 4.6 | 17.3 ± 3.0 | 19.7 ± 5.1 | 21.6 ± 6.2 | 18.6 ± 3.8 |
| Growth velocity, cm/year, mean ± SD | 5.8 ± 2.4 | 5.8 ± 2.4 | 5.6 ± 2.3 | |||
| Growth velocity SDS, mean ± SD | −0.41 ± 2.7 | −0.43 ± 3.2 | −0.46 ± 2.4 | |||
| BA/CA, mean ± SD | 1.31 ± 0.24 | 1.35 ± 0.19 | 1.31 ± 0.26 | 1.25 ± 0.22 | 1.22 ± 0.17 | 1.28 ± 0.27 |
| Tanner breast staging, n | II: 1/26 III: 19/26 IV: 6/26 |
III: 9/10 IV: 1/10 |
II: 1/12 III: 7/12 IV: 4/12 |
I: 1/25 II: 1/25 III: 19/25 IV: 1/25 V: 3/25 |
II: 1/10 III: 8/10 V: 1/10 |
I: 1/12 III: 8/12 IV: 1/12 V: 2/12 |
| Testicular volume, mL | 4–15 (n = 7) | 4, 10 (n = 2) | 5, 10, 12, 12, 15 (n = 5) | 5–10 (n = 7) | 5, 7 (n = 2) | 5, 8, 8, 9, 9 (n = 5) |
| Menarche | 2 (8) | 0 (0) | 2 (16) | 0 (0) | 0 (0) | 0 (0) |
BA/CA, bone age to chronological age ratio; BMI, body mass index; CNS, central nervous system.
P value not significant for all comparisons between patients with prepubertal and pubertal US LH values.